Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$28.47 USD
+0.38 (1.35%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $28.47 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
CSTL 28.47 +0.38(1.35%)
Will CSTL be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CSTL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CSTL
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CSTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
Zacks Market Edge Highlights: Soundhound AI, Afya, Castle Biosciences, TriMas and Immersion
5 Top Small Cap Stocks to Buy Now
Other News for CSTL
BTIG life sciences/diagnostics analyst holds an analyst/industry conference call
BTIG life sciences/diagnostics analyst holds an analyst/industry conference call
New Data at ASTRO 2024 Shows Castle Biosciences? DecisionDx?-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
The Melanoma Research Foundation to host the Los Angeles Miles for Melanoma 5K
BTIG life sciences/diagnostics analyst holds an analyst/industry conference call